FRONTEO Exhibits and Presents at AI Drug Discovery & Development Summit 2026 in the United States

Proprietary AI “KIBIT” Attracts Strong Interest and Positive Feedback from Global Pharmaceutical Companies for Its “Discontinuous Discovery” Approach and Drug Discovery Research Achievements

Tokyo, Japan, November 11, 2026 - FRONTEO, Inc. (Headquarters: Tokyo, Japan; President & CEO: Masahiro Morimoto; hereinafter “FRONTEO”) announces that it exhibited as a Platinum Partner at the AI Drug Discovery & Development Summit 2026 (hereinafter “AIDDD”), an international conference focused on AI-driven drug discovery and development, held in Boston, Massachusetts, from October 27 to 29, 2026. Hiroyoshi Toyoshiba, Director & Chief Science Officer (CSO) of FRONTEO, also delivered a presentation at the conference. 

Hiroyoshi Toyoshiba, Director & CSO, delivered a presentation titled
 “Can AI Discover Biology That Has Never Been Reported?”

AIDDD brings together leading global pharmaceutical companies, research institutions, and other organizations involved in AI-driven drug discovery and development. FRONTEO showcased its AI-driven drug discovery support service “Drug Discovery AI Factory” (hereinafter “DDAIF”) at its exhibition booth. At the Discovery Biology Stage, Toyoshiba presented FRONTEO's technology for identifying novel drug targets using its proprietary Equation-driven AI “KIBIT,” along with the company's research findings.

The presentation attracted the audience of more than 200 attendees, primarily R&D professionals from leading global pharmaceutical companies, and generated strong interest in “discontinuous discovery.”

In his presentation, “Can AI Discover Biology That Has Never Been Reported?”, Toyoshiba explained FRONTEO's approach to “discontinuous discovery,” which differs from AI approaches that primarily integrate and organize existing knowledge. By analyzing vast amounts of medical literature, KIBIT predicts previously unreported relationships between diseases and target molecules. Toyoshiba also introduced a research case in which DDAIF identified novel drug target candidates for pancreatic cancer within a short period, with subsequent in vitro experiments confirming inhibitory effects on cell proliferation. In addition to drug target identification, he highlighted DDAIF's broad potential applications, including indication discovery, drug repositioning, and biomarker discovery.

The presentation generated considerable interest, and many attendees, including R&D professionals from leading global pharmaceutical companies, visited FRONTEO's booth afterward. Visitors asked numerous questions about the mechanisms underlying FRONTEO's proprietary technology for discontinuous discovery, as well as its specific research findings and track record, leading to active discussions. Particular attention was given to FRONTEO's extensive collaborative research experience with companies and academic institutions in Japan and overseas, and to the progress of its research from AI-driven hypothesis generation to experimental validation, as demonstrated by its work on identifying novel drug targets for pancreatic cancer.

Participation by leading global pharmaceutical companies, biotechnology companies, and AI and GPU cloud service providers.

FRONTEO's participation in AIDDD reaffirmed that identifying highly novel drug targets is a major challenge shared by pharmaceutical companies and research institutions worldwide, and highlighted strong demand for FRONTEO's AI technology capable of enabling discontinuous discovery. The positive feedback on FRONTEO's proprietary technology and research achievements also provided an opportunity to reaffirm DDAIF's competitiveness and potential for business expansion.

Building on these achievements, FRONTEO will further accelerate the global expansion of its DDAIF business. The company will actively pursue new collaboration opportunities with pharmaceutical companies and research institutions overseas, contributing to the development of innovative therapeutics and addressing unmet medical needs.

About AI Drug Discovery & Development Summit 2026

The AI Drug Discovery & Development Summit is an international conference dedicated to the application of AI across drug discovery and development. The fifth annual summit, held in 2026, brought together representatives from leading global pharmaceutical companies, biotechnology companies, and academia. Participants shared the latest advances and practical applications of AI in pharmaceutical R&D, covering areas such as discovery biology, discovery chemistry, and clinical trials.
Dates: October 27–29, 2026
Venue: Boston Marriott Copley Place, Boston, Massachusetts, USA
Organizer: Kisaco Research
Official Website: https://www.aidrivendrugdevelopment.com/

About FRONTEO Drug Discovery AI Factory (DDAIF)

[Reference: Initiatives with pharmaceutical companies and Academia]
https://www.fronteo.com/news/ddaif-list

FRONTEO Drug Discovery AI Factory (DDAIF) is an AI-based drug discovery support service that combines KIBIT (patented in Japan, Europe, the U.S., and South Korea), an Equation-driven AI specialized in natural language processing, with the expertise of FRONTEO’s drug discovery researchers and AI engineers. It powerfully supports researchers’ decision-making in drug development through the analysis of disease-related gene networks and the construction of hypotheses regarding target molecule candidates. This service has already been adopted by multiple major pharmaceutical companies and has a proven track record.

*The technology used in Drug Discovery AI Factory is covered by a total of 21 patents held by FRONTEO in Japan, Europe, the U.S., and South Korea.

https://lifescience.fronteo.com/products/drug-discovery-ai-factory/

About FRONTEO, Inc. https://www.fronteo.com/en/